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The thyroid cell sap inactivated LATS almost completely and even after repeated spinning for another 3 hours at 150,000 g, 77 % of the activity was neutralized by this soluble fraction. With the kidney sap prepared in the same way, there was very little inactivation both before and after further spinning. Thyroid and kidney cell sap had no effect on the activity of bovine TSH, suggesting again that the thyroid was reacting with LATS specifically.
In another experiment we tried to prepare a soluble thyroid extract by a different method. A washed thyroid homogenate was incubated for 1 hour at 370 C with phosphate buffered saline, pH 73, containing 1% BSA to protect the proteins, left overnight at 50 C, then spun down at 150,000 g for 3 hours. The soluble extract reduced LATS activity to the same extent as did the cell sap fraction and the degree of inhibition increased with the amount of tissue used to prepare the extract, taking into account the normal variation observed between different experiments and tissue pools.
These extracts were passed through DEAEcellulose using solutions of increasing ionic strength. Three peaks were obtained, but only the breakthrough in 0 1 M phosphate, pH 6-5, was able to neutralize LATS. Thyroglobulin could not be detected by immunodiffusion against a Hashimoto serum and therefore did not seem to be responsible for the inactivation of LATS in these experiments.
In conclusion, the absorption of LATS by thyroid tissue and its recovery after acid elution are consistent with the view that it is an antibody. The antigenic site is probably thyroid specific though some absorption occurs with kidney and other organs which cannot be attributed solely to nonspecific adsorption of IgG. However, the results with TSH suggest that the effect of kidney is not immunological. The antigen cannot be purified by differential centrifugation. It may be present in the cell membrane, and conventional methods may well distribute the material over all subcellular fractions. In support of this view, Bradbury in collaboration with us has observed by electron microscopy that LATS stimulated the formation of endocytic vacuoles in thyroid epithelial cells as seen by the uptake of ferritinlabelled LATS-IgG. Material which inhibits LATS appears to be extractable in a soluble form. The neutralizing fraction purified by chromatography on DEAE-cellulose does not contain appreciable amounts of thyroglobulin. It has yet to be established that this inhibition represents a true immunological reaction. (Hall et al. 1967 ). We report here our experience of 42 patients referred with this provisional diagnosis. In the event, 26 patients were considered to have ophthalmic Graves' disease, in 6 patients the clinical and laboratory findings were insufficient to reach a firm diagnosis, 2 patients had undergone spontaneous remissions from hyperthyroidism and 8 patients had other diseases responsible for their eye signs.
Clinical Features
The ocular manifestations of Graves' disease consist of exophthalmos, bulging of the eyelids, lid retraction and ophthalmoplegia as well as varying degrees of conjunctival irritation and chenlosis. Of the 26 patients with ophthalmic Graves' disease, 11 had unilateral and 6 bilateral exophthalmos; 9 had bilateral bulging of the eyelids; 11 bad unilateral and 6 bilateral lid retraction; 6 had unilateral and 6 bilateral ophthalmoplegia. Asymmetry of exophthalmos averaged 2 mm, only 1 patient having asymmetry (8 mm) exceeding 5 mm. Most patients presented within 6 months of the onset of symptoms and the duration of follow up ranged from 4 months to 8 years with a mean of 2-4 years. Nine of the patients had significant thyroid enlargement, 4 had a past history suggestive of an episode of ocular Graves' disease, 6 had a family history of thyroid or other organ-specific autoimmune disease and 2 suffered from vitiligo (Cunliffe et al. 1968 ).
Investigations
Thyroglobulin antibodies were positive in a titre of 1:25 or more in 11/26 patients, thyroidspecific complement-fixing antibodies were positive in 4/26 patients. Raised values of plasma protein bound 1311 (>033% dose/litre plasma) were found in 8/24 patients all, of whom had circulating thyroid antibodies.
Estimations of thyroid uptake of 1311 at 6 and 24 hours were performed in 9 patients before and after thyroid-stimulating hormone (TSH). Four patients showed a significant rise in uptake at 6 hours and 2 at 24 hours, confirming thyroid reserve capacity in these individuals. In the same 9 patients serum protein-bound iodine was estimated before and after TSH. Seven patients showed an increment greater than 4 ,ug/100 ml in PBI, again indicating significant thyroid reserve capacity. This increase in PBI after TSH is similar to that reported by Werner (1955) who found a mean increment of 4-7 pg/100 ml in 8 patients. Half of the 26 patients showed a normal thyroid suppressibility with triiodothyronine.
Conclusions
Ophthalmic Graves' disease can be diagnosed by its clinical presentation alone; a striking feature is the asymmetry of the eye signs. Laboratory investigations are helpful in confirming the diagnosis, circulating thyroid antibodies being demonstrated in half the cases and failure of thyroid suppression being seen in a similar number. From the response in thyroidal 1311 uptake and PBI to TSH it is clear that the majority of patients with ophthalmic Graves' disease have thyroid reserve capacity. This suggests that their euthyroid state is not due to thyroid damage from autoimmune thyroiditis or other processes but is more likely to represent the absence or inadequacy of circulating thyroid-stimulating agents.
